SLAIN2

Across TCGA pan-cancer cohorts, SLAIN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLAIN2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLAIN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLAIN2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where SLAIN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.764	0.453	.003	14	view →
LUAD	OS	Median	III,IV	1.000	0.663	.007	11	view →
HNSC	DFS	Quartile	III,IV	1.000	0.852	.013	8	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
UCEC	DFS	Median	All	0.971	0.841	.006	6	view →
PDAC	DFS	Quartile	III,IV	0.946	0.240	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLAIN2–CCRCC (DFS)

Open the CCRCC breakdown →